Thymalin Research for Post-Viral Immune Dysfunction
An evidence-based overview of research examining Thymalin in the context of post-viral immune dysfunction. This page synthesizes findings from peer-reviewed literature.
Research Summary
A 2021 observational study examined Thymalin in COVID-19 patients, reporting 92% increase in lymphocytes and faster NK-cell normalization. This represents the most recent clinical evidence but was not placebo-controlled and conducted at a single Russian center.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Post-Viral Immune Dysfunction
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Thymalin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.